Eluxadoline is a medication that is most commonly used in managing gastrointestinal illnesses, specifically Irritable Bowel Syndrome (IBS). Eluxadoline functions as a mu-opioid receptor agonist and ensures that bowel movements are regular by slowing down intestinal activity, thus ensuring easier digestion and metabolism.

“This patent is not only a personal achievement, but also a reflection of the guidance, inspiration, and research culture offered by MGM University,” said Dattatreya Chaudhary. “I am very thankful to my mentors, particularly Dr. Suryakant Sapkal and Dr. Suchita Gadekar, for their motivation during this entire process. This success energizes me to keep breaking barriers in pharmaceutical chemistry.”

Dattatreya’s success has been widely appreciated on campus. Chancellor Ankushrao Kadam, Vice Chancellor Prof. Dr. Vilas Sapkal, Registrar Dr. Ashish Gadekar, Dean Dr. Prapti Deshmukh, Director Dr. Annasaheb Khemnar, Dr. K. M. Jadhav, and other senior faculty members have extended warm greetings and best wishes for his future success.

“Dattatreya’s achievement is a reflection of the spirit of innovation and academic excellence that MGM University aims to foster,” said Prof. Dr. Vilas Sapkal, Vice Chancellor of MGM University. “Getting a patent as a student is no easy accomplishment—it is a testament to the fact that if they are properly mentored and supported by the institution, our scholars can deliver contributions of national and international importance. We are proud of his contribution and believe that it will encourage many more to go for research with a purpose.”

The work was performed under the supervision of Dr. Suryakant Sapkal, Head of Chemistry Department, and Dr. Suchita Gadekar, who provided academic supervision and technical support throughout the project.